Fig. 3From: A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s diseaseBiomarker performance of Aβ42/Aβ40 and Aβ42/Aβ38 ratios in plasma. ROC analyses for Aβ42/Aβ40 and Aβ42/Aβ38 ratios for classification of OD vs AD-D. For both ROC curves, null hypothesis that AUCs were equal to 0.5 could be rejected (p < 0.001 for Aβ42/Aβ40 ratio and p = 0.0013 for Aβ42/Aβ38 ratio). Aβ amyloid beta, AUC area under the curveBack to article page